Supplementary Materials

The PDF file includes:

  • Fig. S1. Schematic overview and timeline of the experimental setting for the longitudinal analysis of convalescent donors after SARS-CoV-2 infection.
  • Fig. S2. IFN-γ ELISPOT assays of longitudinal SARS-CoV-2 T cell responses in convalescent individuals.
  • Fig. S3. Control ex vivo IFN-γ ELISPOT assay for validation of T cell response intensities between T1 and T2.
  • Fig. S4. Kinetics of T cell response intensity to cross-reactive epitope compositions in individual convalescent donors.
  • Fig. S5. Flow cytometry-based characterization of long-term SARS-CoV-2specific T cell responses.
  • Fig. S6. Flow cytometry-based characterization of CD8+ T cell responses at T1 and T2.
  • Fig. S7. Flow cytometry-based characterization of CD4+ T cell responses at T1 and T2.
  • Fig. S8. Longitudinal flow cytometry-based analysis of SARS-CoV-2 T cell response.
  • Fig. S9. Longitudinal assessment of SARS-CoV-2-directed antibody responses.
  • Fig. S10. Correlation of SARS-CoV-2 antibody response with intensity of T cell responses at T2.
  • Fig. S11. Diversity of T cell responses to HLA-A*24-restricted peptides in convalescent donors over time.
  • Fig. S12. Longitudinal assessment of SARS-CoV-2 T cell response diversity in different subgroups of HLA-DR-restricted peptides.
  • Fig. S13. Longitudinal assessment of SARS-CoV-2 T cell responses to HLA-DR- and HLA-A*24-restricted SARS-CoV-2-derived peptides.
  • Fig. S14. Gating strategy for flow cytometry-based evaluation of surface marker and intracellular cytokine staining.
  • Table S1. Clinical characteristics of convalescent donors.
  • Table S2. Characteristics of individual convalescent donors.
  • Table S3. PCR retesting of convalescent donors with post-infectious symptoms at T2.
  • Table S4. SARS-CoV-2-specific and cross-reactive HLA class I- and HLA-DRrestricted T cell epitope compositions.
  • Table S5. Intensity of T cell and antibody response at T2 according to gender, age, and BMI.
  • Table S6. Longitudinal characterization of SARS-CoV-2-derived HLA-DRrestricted peptides.
  • Table S7. Longitudinal characterization of SARS-CoV-2-derived HLA-A*24restricted peptides.
  • Table S8. Control peptides.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: